Novartis to Acquire IFM Tre for its Clinical and Preclinical Portfolio of NLRP3 Inhibitors for $1.5B

 Novartis to Acquire IFM Tre for its Clinical and Preclinical Portfolio of NLRP3 Inhibitors for $1.5B

Novartis to Acquire IFM Tre for its Clinical and Preclinical Portfolio of NLRP3 Inhibitors for $1.5B

Shots: 

  • Novartis acquires IFM Tre, in all stock transaction for $1.575B. IFM Tre to receive $310M upfront & $1.265B milestones from Novartis. The transaction is expected to close in Q2’19
  • The focus of the acquisition is to expand Novartis’ immunomodulatory portfolio with the addition of IFM Tre’s one clinical (IFM-2427) and two preclinical programs of NLRP3 inhibitors targeting NLRP3 inflammasome to treat multiple metabolic, fibrotic, autoimmune, and neurological diseases
  • IFM-2427 is a clinical stage antagonist targeted for chronic inflammatory disorders, including gout, atherosclerosis and nonalcoholic steatohepatitis (NASH)

Click here to read full press release/ article | Ref: IFM Therapeutics | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post